文章摘要
叶丽虹,余小君,吴 轲,林惠萍,简瑞贤.超声心动图参数联合血清NT-pro BNP、suPAR、PTX-3预测慢性心力衰竭患者预后的临床研究[J].,2023,(18):3479-3483
超声心动图参数联合血清NT-pro BNP、suPAR、PTX-3预测慢性心力衰竭患者预后的临床研究
Clinical Study of Echocardiographic Parameters Combine with Serum NT-pro BNP, suPAR, PTX-3 in Predicting the Prognosis of Patients with Chronic Heart Failure
投稿时间:2023-02-21  修订日期:2023-03-17
DOI:10.13241/j.cnki.pmb.2023.18.015
中文关键词: 超声心动图参数  NT-pro BNP  suPAR  PTX-3  慢性心力衰竭  预后  预测价值
英文关键词: Echocardiographic parameters  NT-pro BNP  suPAR  PTX-3  Chronic heart failure  Prognosis  Predictive value
基金项目:福建省医学创新课题资助计划项目(2018-CX-42)
作者单位E-mail
叶丽虹 联勤保障部队第909医院(厦门大学附属东南医院)超声诊断科 福建 漳州 363000 15605060079@163.com 
余小君 联勤保障部队第909医院(厦门大学附属东南医院)超声诊断科 福建 漳州 363000  
吴 轲 联勤保障部队第909医院(厦门大学附属东南医院)心血管内科 福建 漳州 363000  
林惠萍 联勤保障部队第909医院(厦门大学附属东南医院)超声诊断科 福建 漳州 363000  
简瑞贤 联勤保障部队第909医院(厦门大学附属东南医院)超声诊断科 福建 漳州 363000  
摘要点击次数: 409
全文下载次数: 262
中文摘要:
      摘要 目的:探讨超声心动图参数联合血清N末端B型脑钠肽前体(NT-pro BNP)、可溶性尿激酶型纤溶酶原激活物受体(suPAR)、正五聚体蛋白-3(PTX-3)预测慢性心力衰竭(CHF)患者预后的临床价值。方法:选取2019年1月-2021年10月联勤保障部队第909医院收治的122例CHF患者作为CHF组,同期选取50例体检健康者作为对照组。比较两组超声心动图参数和血清NT-pro BNP、suPAR、PTX-3水平。CHF患者出院后随访12个月,根据预后情况分为预后不良组和预后良好组,并比较两组超声心动图参数和血清NT-pro BNP、suPAR、PTX-3水平。受试者工作特征(ROC)曲线分析超声心动图参数联合血清NT-pro BNP、suPAR、PTX-3对CHF患者预后不良的预测价值。结果:与对照组比较,CHF组左心室舒张末期直径(LVEDD)、左心室收缩末期直径(LVESD)、NT-pro BNP、suPAR、PTX-3显著升高(P<0.05),左心室射血分数(LVEF)显著降低(P<0.05)。122例CHF患者出院后随访12个月,其中预后不良患者35例、预后良好患者83例。与预后良好组比较,预后不良组LVEDD、LVESD、NT-pro BNP、suPAR、PTX-3显著升高(P<0.05),LVEF显著降低(P<0.05)。ROC曲线分析结果显示,LVEDD、LVESD、LVEF联合NT-pro BNP、suPAR、PTX-3预测CHF预后不良的效能最高,显著优于各项指标单独预测。结论:超声心动图参数LVEDD、LVESD、LVEF联合血清NT-pro BNP、suPAR、PTX-3预测CHF患者预后不良的价值较高,可作为预测CHF患者预后的辅助指标。
英文摘要:
      ABSTRACT Objective: To explore the clinical value of echocardiography parameters combine with serum N-terminal B-type brain natriuretic peptide (NT-pro BNP), soluble urokinase type plasminogen activator receptor (suPAR), and pentraxin-3 (PTX-3) in predicting the prognosis of patients with chronic heart failure (CHF). Methods: 122 patients with CHF who were admitted to the 909th Hospital of the Joint Logistics Support Force from January 2019 to October 2021 were selected as the CHF group, while 50 healthy individuals were selected as the control group during the same period. The echocardiographic parameters and serum NT-pro BNP, suPAR, and PTX-3 levels were compared between the two groups. Patients with CHF were followed up for 12 months after discharge, and they were divided into poor prognosis group and good prognosis group based on the prognosis, and the echocardiographic parameters and serum NT-pro BNP, suPAR, and PTX-3 levels were compared between the two groups. The predictive value of receiver operating characteristic (ROC) curve analysis of echocardiography parameters combined with serum NT pro BNP, suPAR, and PTX-3 for poor prognosis of patients with CHF. Results: Compared with the control group, left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), NT-pro BNP, suPAR, and PTX-3 of the CHF group were significantly increased (P<0.05), while left ventricular ejection fraction (LVEF) was significantly decreased (P<0.05). 122 patients with CHF were followed up for 12 months after discharge, including 35 patients with poor prognosis and 83 patients with good prognosis. Compared with the good prognosis group, LVEDD, LVESD, NT-pro BNP, suPAR, and PTX-3 of the poor prognosis group significantly increased (P<0.05), while LVEF significantly decreased (P<0.05). ROC curve analysis results showed that LVEDD, LVESD, and LVEF combined with NT-pro BNP, suPAR, and PTX-3 had the highest efficacy in predicting poor prognosis of CHF, significantly superior to the individual predictin of various indicators. Conclusion: Echocardiographic parameters LVEDD, LVESD, and LVEF combine with serum NT-pro BNP, suPAR, and PTX-3 have a high value in predicting poor prognosis of patients with CHF, which can serve as an auxiliary indicator for predicting the prognosis of patients with CHF.
查看全文   查看/发表评论  下载PDF阅读器
关闭